Literature DB >> 8787871

Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility.

S P Klemens1, C A Sharpe, M H Cynamon.   

Abstract

The activity of pyrazinamide (PZA) against eight isolates of Mycobacterium tuberculosis in a murine infection model was evaluated. M. tuberculosis isolates with various degrees of in vitro susceptibility to PZA (MIC range, 32 to > 2,048 micrograms/ml) were used. Four-week-old female mice were infected intravenously with approximately 10(7) viable M. tuberculosis organisms. PZA at 150 mg/kg of body weight was started 1 day postinfection and given 5 days/week for 4 weeks. Infected but untreated mice were compared with PZA-treated mice. Mice were sacrificed at the completion of the treatment period, and viable cell counts were determined from homogenates of spleens and right lungs. PZA had activity in the murine test system against M. tuberculosis isolates for which the MICs were < or = 256 micrograms/ml. However, there was an inconsistent correlation between the absolute MICs and the reductions in organ viable cell counts. Studies with drug-resistant M. tuberculosis isolates with an isogenic background would improve evaluation of drug efficacy in the murine test system. Further evaluation of antimycobacterial agents against monodrug-resistant isolates will provide data that will be useful for development of algorithms for treatment of infection with drug-resistant organisms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8787871      PMCID: PMC163048     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.

Authors:  H F Lecoeur; C Truffot-Pernot; J H Grosset
Journal:  Am Rev Respir Dis       Date:  1989-11

2.  Activation of pyrazinamide and nicotinamide in acidic environments in vitro.

Authors:  W McDERMOTT; R TOMPSETT
Journal:  Am Rev Tuberc       Date:  1954-10

3.  Absorption, metabolism and excretion of pyrazinamide in man.

Authors:  G A Ellard
Journal:  Tubercle       Date:  1969-06

4.  Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity.

Authors:  W R Butler; J O Kilburn
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

5.  Pyrazinamide (aldinamide) in experimental tuberculosis of the guinea pig.

Authors:  F I DESSAU; R L YEAGER; F J BURGER; J H WILLIAMS
Journal:  Am Rev Tuberc       Date:  1952-05

6.  The effect of pyrazinamide (aldinamide) on experimental tuberculosis in mice.

Authors:  L MALONE; A SCHURR; H LINDH; D McKENZIE; J S KISER; J H WILLIAMS
Journal:  Am Rev Tuberc       Date:  1952-05

7.  Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?

Authors:  L B Heifets; M A Flory; P J Lindholm-Levy
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

8.  Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli.

Authors:  M A Fischl; G L Daikos; R B Uttamchandani; R B Poblete; J N Moreno; R R Reyes; A M Boota; L M Thompson; T J Cleary; S A Oldham
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

Review 9.  Drug treatment of tuberculosis--1992.

Authors:  P T Davidson; H Q Le
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

10.  Therapy of multidrug-resistant tuberculosis: lessons from studies with mice.

Authors:  S P Klemens; M S DeStefano; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

View more
  9 in total

Review 1.  The Bewildering Antitubercular Action of Pyrazinamide.

Authors:  Elise A Lamont; Nicholas A Dillon; Anthony D Baughn
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

2.  Long-Chain Fatty Acyl Coenzyme A Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.

Authors:  Brandon C Rosen; Nicholas A Dillon; Nicholas D Peterson; Yusuke Minato; Anthony D Baughn
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

3.  Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.

Authors:  A Scorpio; P Lindholm-Levy; L Heifets; R Gilman; S Siddiqi; M Cynamon; Y Zhang
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

4.  Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives.

Authors:  Laura E Via; Rada Savic; Danielle M Weiner; Matthew D Zimmerman; Brendan Prideaux; Scott M Irwin; Eddie Lyon; Paul O'Brien; Pooja Gopal; Seokyong Eum; Myungsun Lee; Jean-Philippe Lanoix; Noton K Dutta; TaeSun Shim; Jeong Su Cho; Wooshik Kim; Petros C Karakousis; Anne Lenaerts; Eric Nuermberger; Clifton E Barry; Véronique Dartois
Journal:  ACS Infect Dis       Date:  2015-05-08       Impact factor: 5.084

5.  The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells.

Authors:  Susana Mendez; Ryan Traslavina; Meleana Hinchman; Lu Huang; Patricia Green; Michael H Cynamon; John T Welch
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

6.  Pantothenate and pantetheine antagonize the antitubercular activity of pyrazinamide.

Authors:  Nicholas A Dillon; Nicholas D Peterson; Brandon C Rosen; Anthony D Baughn
Journal:  Antimicrob Agents Chemother       Date:  2014-09-22       Impact factor: 5.191

7.  Docking studies and network analyses reveal capacity of compounds from Kandelia rheedii to strengthen cellular immunity by interacting with host proteins during tuberculosis infection.

Authors:  Aubhishek Zaman
Journal:  Bioinformation       Date:  2012-10-31

8.  Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA.

Authors:  Nicholas A Dillon; Nicholas D Peterson; Heather A Feaga; Kenneth C Keiler; Anthony D Baughn
Journal:  Sci Rep       Date:  2017-07-21       Impact factor: 4.379

9.  In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1.

Authors:  Pooja Gopal; Rokeya Tasneen; Michelle Yee; Jean-Philippe Lanoix; Jansy Sarathy; George Rasic; Liping Li; Véronique Dartois; Eric Nuermberger; Thomas Dick
Journal:  ACS Infect Dis       Date:  2017-03-16       Impact factor: 5.084

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.